Influenza A virus A/Kansas/14/2017 (H3N2) live (attenuated) antigen

DB15514ApprovedWithdrawnVaccines

Influenza A virus A/Kansas/14/2017 (H3N2) live (attenuated) antigen is a live attenuated influenza antigen used in season influenza vaccines. A seasonally-specific component of the influenza vaccine.

First approval: United States, 2019

Resolves to

Compound

UNII481B6U9IO3

What you can answer from here — as of April 02, 2025

1Structured indicationCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

6Marketed productsAcross 2 countries and 4 labellers

1+ReferenceStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Influenza A virus A/Kansas/14/2017 (H3N2) live (attenuated) antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account